JPRN-jRCT2080221041未知3 期
A Phase3, 12-week, Double-blind, Randmised, Parallel-group, Active-controlled, Multinational, Efficacy and Safety Study of Symbicort Turbuhaler 160/4.5mcg 2 Inhalations Bid Compared to Oxis Turbuhaler 4.5mcg 2 Inhalations Bid in Patients With Chronic Obstructive Pulmonary Disease
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 ot applicable（—）
- 性别
- All
入选标准
- •A current clinical diagnosis of COPD
- •- Documented COPD symptoms for more than 2 years
- •- A smoking history of at least 10 pack years
排除标准
- •- History and/or current clinical diagnosis of asthma
- •- History and/or current clinical diagnosis of atopic diseases such as allergic rhinitis
研究者
相似试验
已完成
3 期
SUMIRE (Symbicort in COPD patients)CTRI/2010/091/000153AstraZeneca AB120
进行中（未招募）
1 期
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 µg and Symbicort pMDI 80/4.5 µg, Compared with Budesonide pMDI 80 µg.AsthmaEUCTR2013-005293-22-SKAstraZeneca AB279
招募中
1 期
A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Openlabel Extension of BLU-5937 in Adult Participants with Refractory or Unexplained Chronic Cough (CALM-2)Refractory Chronic Cough, Including Unexplained Chronic CoughMedDRA version: 21.0Level: LLTClassification code: 10080782Term: Refractory chronic cough Class: 10038738MedDRA version: 21.1Level: LLTClassification code: 10066656Term: Chronic cough Class: 10038738CTIS2024-513462-19-00Bellus Health Inc.771
尚未招募
3 期
A Phase 3 study to determine Efficacy and Safety Study of BLU-5937 in Adult Participants with Refractory Chronic Cough.CTRI/2023/11/060301Bellus Health, Inc.
尚未招募
3 期
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)JPRN-jRCT2031230611Kawamoto Mika825